AET EU 2026 x KACTUS

By Hannah Flaherty

May 19, 2026

Menu

What is the Protein Engineering & Cell Therapy Summit?

The Antibody Engineering & Therapeutics (AET) conference is a premier annual event that brings together scientists, researchers, and industry professionals from biotechnology and pharmaceutical sectors to explore advancements in antibody-based therapeutics. This conference focuses on cutting-edge research, innovation, and development strategies in antibody engineering, bispecifics, antibody-drug conjugates (ADCs), immune-oncology, and next-generation therapeutic modalities.

Event Overview

Venue: Congress Center Basel, Messeplatz 21, 4058 Basel, Switzerland

Dates: May 27–29, 2026

Conference Day 1: Wednesday, May 27, 2026 – 7:00 AM to 6:45 PM

Networking Cocktail Reception and Exhibit/Poster Viewing: 5:45 PM to 6:45 PM

Conference Day 2: Thursday, May 28, 2026 – 7:15 AM to 6:00 PM

Exhibit Hall Hours: 7:15 AM to 6:00 PM

Conference Day 3: Friday, May 29, 2026 – 8:30 AM to 5:15 PM

Exhibit Hall Hours: 8:30 AM to 5:15 PM

Booth #27

Event Schedule

AET Europe offers a focused exploration of the latest tools, platforms, and strategies advancing antibody and protein therapeutic development. The three-day event features scientific sessions, poster presentations, and curated networking opportunities designed to spark collaboration and accelerate discovery. Explore the full AET agenda for a detailed look at what’s ahead.

Day 1: Wednesday, May 27, 2026

Registration, Coffee and Exhibit/Poster Viewing from 7:15 AM to 8:00 AM
Chairperson’s Remarks at 8:00 AM
Keynote Presentations from 8:05 AM to 10:50 AM
Networking Refreshment Break and Exhibit/Poster Viewing at 9:40 AM
Scientific Briefings from 11:30 AM to 1:30 PM
Networking Luncheon and Exhibit/Poster Viewing at 12:30 PM
Afternoon Scientific Track Sessions from 2:00 PM onward
Networking Refreshment Break and Exhibit/Poster Viewing at 3:35 PM
Networking Cocktail Reception and Exhibit/Poster Viewing from 5:45 PM to 6:45 PM
Exhibit Hall Hours from 7:15 AM to 6:45 PM

Day 2: Thursday, May 28, 2026

Registration, Coffee and Exhibit/Poster Viewing beginning at 7:15 AM
Scientific Briefings from 7:40 AM to 8:10 AM
Morning Scientific Track Sessions from 8:15 AM onward
Networking Refreshment Break and Exhibit/Poster Viewing at 9:50 AM
Scientific Presentations and Technical Sessions throughout the morning
Scientific Briefings at 11:50 AM and 12:20 PM
Networking Luncheon and Exhibit/Poster Viewing at 12:50 PM
Afternoon Scientific Track Sessions from 2:20 PM onward
Networking Refreshment Break and Exhibit/Poster Viewing at 3:55 PM
Final Afternoon Scientific Sessions through 5:55 PM
Close of Day Two at 5:55 PM
Exhibit Hall Hours from 7:15 AM to 6:00 PM

Day 3: Friday, May 29, 2026

Registration and Coffee beginning at 8:00 AM
Scientific Briefings from 8:20 AM to 8:50 AM
Morning Scientific Sessions from 8:55 AM onward
Networking Refreshment Break at 10:30 AM
Mid-Morning Scientific Presentations from 11:00 AM onward
Scientific Briefings at 12:30 PM
Networking Luncheon at 1:00 PM
Additional Afternoon Scientific Sessions and Presentations
Exhibit Hall Hours from 8:30 AM to 5:15 PM

Featured Presentation

Designing Epitope-Selective Antibodies: Engineering Approaches to Maximize Target Accessibility and Prevent Hidden Epitope Engagement

Speaker: Anil Kumar, Ph.D., Business Development Manager, DACH Region, KACTUS

Date & Time: Thursday, May 28, 2026 | 1:50 PM–2:20 PM

Presentation Overview:

Epitope-selective antibodies (EsAbs) offer enhanced therapeutic specificity by targeting precise antigen conformations and functionally relevant regions. In this scientific briefing, KACTUS will highlight engineering approaches designed to maximize target accessibility while minimizing unproductive engagement with hidden or cryptic epitopes.

By leveraging domain- and epitope-specific antigen design strategies, including advanced recombinant protein engineering platforms, KACTUS enables more rational antibody discovery workflows that better guide immune responses toward desired functional regions. These approaches support the development of EsAbs with improved binding profiles, enhanced therapeutic potential, and stronger translational relevance for next-generation antibody therapeutics.

About KACTUS

KACTUS specializes in the development and production of high-quality, bioactive recombinant proteins and enzymes that support innovation across antibody drug discovery, immunotherapy, gene therapy, and mRNA therapeutics. With a catalog of over 2,500 recombinant proteins spanning diverse targets, species, tags, and formats, we are committed to meeting the evolving needs of scientists in translational research. Our focus on rigorous quality control and reliable supply ensures the consistency and performance that today’s therapeutic development demands.